Table 2.
Main outcomes.
| ALL | AML | |||
|---|---|---|---|---|
| Outcomes post HCT % (95% CI) | 5 years | 10 years | 5 years | 10 years |
| RI | 7.1 (6.1−8.1) | 9.9 (8.7−11.2) | 10.1 (9.5−10.8) | 15.6 (14.7−16.5) |
| NRM | 5.6 (4.7−6.5) | 11.9 (10.4−13.4) | 5.9 (5.4−6.4) | 12.1 (11.3−12.9) |
| OS | 90.4 (89.2−91.5) | 81.3 (79.4−83) | 88.1 (87.4−88.8) | 76.2 (75.1−77.3) |
| LFS | 87.3 (86−88.6) | 78.2 (76.3−80) | 84 (83.1−84.7) | 72.3 (71.2−73.4) |
| CGRFS | 83.5 (81.9−84.9) | 73.3 (71.2−75.2) | 80.1 (79.2−81) | 68.1 (66.9−69.2) |
| Chronic GVHD after 2 y | 4.8 (4−5.7) | 6.3 (5.3−7.4) | 4.6 (4.2−5.1) | 5.9 (5.4−6.5) |
Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CGRFS, cGVHD‐free, relapse‐free survival; CI, confidence interval; GVHD, graft‐versus‐host disease; HCT, hematopoietic cell transplantation; LFS, leukemia‐free survival; NRM, nonrelapse mortality; OS, overall survival; RI, relapse incidence.